



CStone Pharmaceuticals

基石藥業

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2616)

24 January 2024

Dear non-registered shareholder(s),

Arrangement of Electronic Dissemination of Corporate Communications

Pursuant to Rule 2.07 of the Rules Governing The Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) under the expansion of paperless listing regime and electronic dissemination of corporate communications that came into effect on 31 December 2023, CStone Pharmaceuticals (the “**Company**”) is writing to inform you that the Company has adopted electronic dissemination of corporate communications (the “**Corporate Communications**”), which mean any documents issued or to be issued by the Company including but not limited to (a) the directors’ report, its annual accounts together with a copy of the auditors’ report and, where applicable, its summary financial report; (b) the interim report and, where applicable, its summary interim report; (c) a notice of meeting; (d) a listing document; (e) a circular and (f) a proxy form.

Please note that both the English and Chinese versions of all future Corporate Communications will be available electronically on the website of the Company at www.cstonepharma.com/ and the HKExnews website at www.hkexnews.hk/ in place of printed copies.

As a non-registered shareholder, if you wish to receive Actionable Corporate Communications^(Note) from the Company pursuant to the Listing Rules, you should liaise with your bank(s), broker(s), custodian(s), nominee(s) or HKSCC Nominees Limited through which your Shares are held (collectively, the “Intermediaries”) and provide your email address to your Intermediaries. It is the responsibility of a non-registered shareholder to provide email address that is functional. The Company will be considered to have complied with the Listing Rules if it sends Actionable Corporate Communications^(Note) to the email address provided by a non-registered shareholder without receiving any “non-delivery message”.

If the Company does not receive your functional email address from the Intermediaries, until such time that the functional email address is provided to the Intermediaries, the Company will send you the Actionable Corporate Communications^(Note) in printed form in the future.

If you want to receive the Corporate Communications in printed form, please complete the reply form electronically at <https://forms.office.com/r/UCFgE1uzuE> or complete and return the reply form on the reverse side to the Company at 22/F, New Bund Times Square, No. 399 West Haiyang Road, Pudong New District, Shanghai, People’s Republic of China.

Should you have any queries relating to this letter, please contact the Company via e-mail at ir@cstonepharma.com.

Yours faithfully,
By order of the Board
CStone Pharmaceuticals
Dr. Wei Li
Chairman

Note: Actionable Corporate Communication is any corporate communication that seeks instructions from issuer’s securities holders on how they wish to exercise their rights or make an election as the issuer’s securities holder.

REPLY FORM 回條

To: CStone Pharmaceuticals (the "Company")
22/F, New Bund Times Square, No. 399 West Haiyang Road,
Pudong New District, Shanghai, People's Republic of China

致： 基石藥業（「本公司」）
中華人民共和國上海市浦東新區
海陽西路 399 號前灘時代廣場 22 樓

REMINDER 提示

As a non-registered shareholder, if you wish to receive Actionable Corporate Communications^(Note 1) pursuant to the Listing Rules, you should liaise with your bank(s), broker(s), custodian(s), nominee(s) or HKSCC Nominees Limited through which your shares are held (collectively, the "Intermediaries") and provide your email address to your Intermediaries.

作為非登記股東，如有意根據《上市規則》收取可供採取行動的公司通訊^(附註 1)，閣下應聯絡代 閣下持有股份的銀行、經紀、託管商、代理人或香港中央結算（代理人）有限公司（統稱「中介公司」），並向 閣下的中介公司提供 閣下的電子郵件地址。

Request for Corporate Communications* in printed form / 要求收取公司通訊*印刷版

(Please mark "✓" in the below box if applicable) (如適用，請在以下方格內劃上「✓」號)

I/we would like to receive future Corporate Communications* in printed form and noted that this instruction is valid only for one year starting from the receipt date of instruction.

本人/我們欲收取未來公司通訊*的印刷版，並已知悉本指示由收取指示日期起計一年內有效。

Provide name of contact person and address by scanning the QR code or returning this Reply Form

掃描二維碼提供地址或交回本回條提供聯絡人姓名及地址

Address 地址: _____

Name of contact person 聯絡人姓名 _____

QR Code

二維碼



Name(s) of Non-registered holder(s):

非登記股東姓名：

(Please use ENGLISH BLOCK LETTERS 請用英文正楷填寫)

Signature(s): ^(Note 4)

簽名： ^(附註 4)

Contact number:

聯絡電話號碼：

Date:

日期：

Notes:

附註：

- Actionable Corporate Communication is any Corporate Communication* that seeks instructions from issuer's securities holders on how they wish to exercise their rights or make an election as the issuer's securities holder.
可供採取行動的公司通訊指任何涉及及要求發行人的證券持有人指示其擬如何行使其有關證券持有人的權利的公司通訊。
- This Reply Form is addressed to non-registered holder(s) ("Non-registered holder" means such person or company whose shares are held in The Central Clearing and Settlement System (CCASS) and who has notified the Company from time to time through Hong Kong Securities Clearing Company Limited that such person or company wishes to receive Corporate Communications*).
此函件乃向本公司之非登記股東（「非登記股東」指股份存放於中央結算及交收系統的人士或公司，已透過香港中央結算有限公司不時向本公司發出通知，表示欲收取公司通訊）發出。
- Please complete all your details clearly.
請 閣下清楚填妥所有資料。
- Any form with no box marked (✓), with no signature or otherwise incorrectly completed will be void.
如在本表格未有在方格內劃上「✓」號，或未有簽署，或在其他方面填寫不正確，則本表格將會作廢。
- For the avoidance of doubt, the Company does not accept any other instructions given on this Reply Form.
為免存疑，在本回條上的任何額外指示，本公司將不予處理。

* Unless otherwise specified, Corporate Communications refer to any documents issued or to be issued by the Company for the information or action of holders of any of its securities, including but not limited to the annual report, interim report, notice of meeting, circular and proxy form.
除非另有註明，公司通訊乃指本公司已發出或將予發出以供其任何證券的持有人參照或採取行動的任何文件，其中包括但不限於年報、中期報告、會議通告、通函及代表委任表格。

PERSONAL INFORMATION COLLECTION STATEMENT

收集個人資料聲明

- "Personal Data" in this statement has the same meaning as "personal data" in the Personal Data (Privacy) Ordinance, Chapter 486 of the Laws of Hong Kong ("PDPO").
本聲明中所指的「個人資料」與香港法例第 486 章《個人資料（私隱）條例》（「《私隱條例》」）中「個人資料」的涵義相同。
- Your Personal Data provided in this Reply Form will be used in connection with the Company's electronic dissemination of Corporate Communications. Your supply of Personal Data to the Company is on a voluntary basis. In case of a failure to provide sufficient information, the Company may not be able to process your instructions and/or requests as stated in this Reply Form. 閣下於本回條所提供的個人資料將用於有關本公司以電子方式發布公司通訊的事宜上。閣下是自願向本公司提供個人資料。若 閣下未能提供足夠資料，本公司可能無法處理 閣下在本回條上所述的指示及/或要求。
- Your Personal Data may be disclosed or transferred by the Company to its subsidiaries, share registrar, and/or other companies or bodies for any of the stated purposes, or when it is required to do so by law and will be retained for such period as may be necessary for our verification and record purposes.
本公司可就任何所說明的用途或在法例規定的情況下，將 閣下的個人資料披露或轉移給本公司的附屬公司、股份過戶處、及/或其他公司或團體，並將在適當期間保留該等個人資料作核實及紀錄用途。
- You have the right to request access to and/or correction of your Personal Data in accordance with the provisions of the PDPO. Any such request for access to and/or correction of your Personal Data should be in writing, by mail to the privacy officer of the Company at 22/F, New Bund Times Square, No. 399 West Haiyang Road, Pudong New District, Shanghai, People's Republic of China or by email at ir@cstonepharma.com.
閣下有權根據《私隱條例》的條文查閱及/或修改 閣下的個人資料。任何該等查閱及/或修改個人資料的要求均須以書面方式郵寄至本公司（地址為中華人民共和國上海市浦東新區海陽西路 399 號前灘時代廣場 22 樓）向隱私主任提出，或發送電郵至 ir@cstonepharma.com。

Mailing Label 郵寄標籤

CStone Pharmaceuticals
基石藥業
22/F, New Bund Times Square, No. 399 West Haiyang Road
Pudong New District, Shanghai, People's Republic of China
中華人民共和國上海市浦東新區
海陽西路 399 號前灘時代廣場 22 樓

Please cut the mailing label and stick it on an envelope to return this form to.

當 閣下寄回此回條時，請將郵寄標籤剪貼於信封上。